期刊
JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY
卷 28, 期 9, 页码 582-605出版社
MARY ANN LIEBERT, INC
DOI: 10.1089/cap.2018.0037
关键词
antipsychotics; psychotic disorders; attention-deficit; hyperactivity disorder; mood disorders; psychopharmacology; children and adolescents
资金
- Aevi
- Akili
- Alcobra
- Amerex
- American Academy of Child AMP
- Adolescent Psychiatry
- American Psychiatric Press
- Bracket
- Epharma Solutions
- Forest
- Genentech
- Guilford Press
- Ironshore
- Johns Hopkins University Press
- KemPharm
- Lundbeck
- Merck
- NIH
- Neurim
- Nuvelution
- Otsuka
- PCORI
- Pfizer
- Physicians Postgraduate Press
- Purdue
- Roche
- Sage
- Shire
- Sunovion
- Supernus Pharmaceuticals
- Syneurx
- Teva
- Tris
- TouchPoint
- Validus
- WebMD
Objectives: The use of atypical antipsychotic medications in pediatric patients has become more prevalent in recent years. The purpose of this review is to provide a clinically relevant update of recent selected key publications regarding the use of atypical antipsychotics in this population. Methods: Studies reviewed included randomized, double-blind, placebo-controlled medication trials conducted within the past 5 years. A PubMed search was conducted for each of the 11 second-generation antipsychotic medications currently approved by the Food and Drug Administration for use in the United States: clozapine, risperidone, olanzapine, quetiapine, aripiprazole, ziprasidone, paliperidone, asenapine, iloperidone, lurasidone, and cariprazine. Trials published in English with subjects 18 years of age and younger were included in this review. Additional studies, chosen for their significance to clinical practice, were also included at the discretion of the authors. Results: This review demonstrates that more empiric data are available regarding both the acute efficacy and, to a lesser extent, the longer-term efficacy and tolerability for several of the considered antipsychotic medications. The clinical conditions for which these medications have been studied include schizophrenia, bipolar disorder, Tourette's disorder, and autism spectrum disorder. They have also been used as an adjunctive treatment for disruptive behavior disorders with aggression, which have not responded to treatment with stimulants. Conclusion: Evidence regarding the efficacy and tolerability of antipsychotic medications for mental health disorders in children and adolescents has expanded exponentially in recent years. However, more information is needed so that evidence-based comparisons between medications can be made. In the future, data enabling the selection of medications based upon individual patient characteristics could potentially lead to greater efficacy and efficiency in treating what are frequently debilitating medical conditions. Maladaptive aggression in children, often treated with antipsychotics, is one such area in which there is a dearth of actual information available to the clinician. It is to be hoped that additional, longer-term studies of these medications will further inform evidence-based practice in clinical settings.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据